Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Abstract: A method for designing a loudspeaker excursion estimator comprises measuring an excursion-related parameter for a loudspeaker, for each of a plurality of loudspeaker input signal levels and each of a plurality of loudspeaker input signal frequencies. The method further comprises, for each of the loudspeaker input signal frequencies and based on the measured excursion-related parameters, identifying a respective loudspeaker input signal level corresponding to a target maximum excursion-related parameter value. The method further comprises determining a filter response, based on the identified loudspeaker input signal levels and their respective loudspeaker input signal frequencies, and implementing a filter, based on the calculated filter response, for generating an excursion estimation based on loudspeaker input signal levels.

Abstract: A method for providing a semisynthetic .beta.-lactam antibiotic by enzyme catalyzed acylation of the parent .beta.-lactam with an activated derivative of the side chain acid wherein a modulator, which consists of one or more compounds different from the reactants and the reaction product and which suppresses the hydrolysis of the activated derivative of the side chain acid and the desired product more than it suppresses the synthesis of the desired product, is added to the reaction mixture, at the beginning of the reaction process, in a concentration from about 0.2 to 100.times.10.sup.3 .mu.m.

Abstract: Therapeutic treatment of cardiac arrhythmia in mammals by oral or parenteral administration of certain substituted .gamma.-piperidino-butyrophenones or the acid-addition salts thereof.